Effects of GSK1070806 (anti-IL18 mAb) on biomarkers in synovial tissue and blood of patients with rheumatoid arthritis.

尽管近年来新疗法的引入极大地改善了类风湿关节炎患者的前景，但仍有相当大的需求未得到满足。这项工作将评估一种潜在的新作用模式，可用于早期或已建立的类风湿性关节炎，以阻止疾病的进展。我们将评估GSK1070806（一种靶向关节炎症信使的新药）诱导的滑膜组织（关节周围的膜，关节炎炎症的靶点）炎症的变化。将在3个中心招募13名患者。我们的探索性目标将研究滑膜炎症的变化，通过一系列尖端的方法进行评估。安全性和耐受性也将进行评估。

Although the introduction of novel therapies has greatly improved the outlook for patients with rheumatoid arthritis over the years, considerable unmet needs remain. This work will evaluate a potential new mode of action that could be used in early or established rheumatoid arthritis to halt the progression of disease. We will evaluate changes in inflammation observed in the synovial tissue (the membrane around the joint, target of inflammation in arthritis) induced by GSK1070806, a new drug targeting a messenger of inflammation present in the joint. 13 patients will be recruited across 3 centers. Our exploratory objectives will study changes in synovial inflammation evaluated by a range of cutting edge methodologies. Safety and tolerance will also be assessed.